| Literature DB >> 29225934 |
Valerie Ann Luyckx1, Nikola Biller-Andorno1, Abha Saxena2, Nhan T Tran3.
Abstract
Given the focus on health systems in the post-millennium development goal era and moving towards the sustainable development goals, there is a compelling need for a common framework for health policy and systems research ethics to guide researchers and facilitate review by research ethics committees. A consultation of global health policy and systems research and ethics experts was convened to identify ethical considerations relevant to health policy and systems research based on existing knowledge and to identify knowledge gaps through a scoping review and further expert deliberation. Health policy and systems research is highly complex and, in the absence of guidance documents, there is significant variability in ethics review. Although fundamental ethical principles pertain to both traditional clinical research and health policy and systems research, the application of these principles requires a comprehensive understanding of the nature of health policy and systems research with its distinct challenges. Such awareness must be raised among researchers and research ethics committees. Current research ethics committees lack familiarity with health policy and systems research and because health policy and systems research is conducted in real-world contexts, committees often have difficulties in determining whether a project is indeed research and/or requires ethical review. Given the strong current focus on health policy and systems research to rapidly improve health and health systems functioning globally, greater engagement and dialogue around the ethical concerns is required to optimise research review and research conduct in this rapidly evolving field.Entities:
Keywords: Health policy and systems research; capacity building; ethical principles; ethics review; research ethics committees
Year: 2017 PMID: 29225934 PMCID: PMC5717951 DOI: 10.1136/bmjgh-2017-000314
Source DB: PubMed Journal: BMJ Glob Health ISSN: 2059-7908
Relevance of ethical considerations in health policy and systems research versus clinical research
| Ethical principle | Ethical consideration | Health policy and systems research | Clinical research | Public health research |
| General considerations | Purpose | Address healthcare disparities | Answer questions related to specific disease process/intervention | Identification of population health determinants, disease levels, establishing effectiveness, safety and costs of public health interventions |
| Methods | Variable, often multidisciplinary | Ideally randomised controlled trial, variable | Variable, may be multidisciplinary | |
| Need for ethical review? | Blurred line between research and practice | Usually required for research | Blurred line between public health interventions and research | |
| Research versus quality improvement, Monitoring and Evaluation (which may not require review) | Nature of public health interventions, observational studies, programme evaluation (which may not require review) | |||
| Data review (no human subjects) | ||||
| Type of intervention | Is study addressing a local health priority? | May be very specific/detached from public health priorities | Should address a locally relevant public health question | |
| Is the study responsive to local health needs? | ||||
| Study context | Embedded within health system, interdependent relationships, social context | Typically controlled circumstances for study, strict inclusion/exclusion criteria | Public health system, community, pragmatic real-life conditions | |
| Local health system, not controllable | ||||
| Ancillary care | Need to consider who is responsible, link with standards of care | May/not be relevant | May be relevant | |
| Data | May be very large databases on whole communities/institutions | Usually strict rules governing privacy, etc. | May be very large databases on whole communities | |
| Who owns the data? | Researchers often “own” data | Usually public health system | ||
| How to ensure privacy? | Subject de-identification, individual consent accept risks | Community members may not be aware that their data are being collected | ||
| Responsibility for post-study care | Scalability/sustainability–state responsibility | Often limited post-study obligations to study participants only — study funders, researchers | Public health programmes should be ongoing if effective | |
| Accountability | Researchers, state, funders? | Researchers, sponsors | Public health policy makers and practitioners | |
| Obligation for health system strengthening | Yes | Not usually primary goal | Not usually primary goal | |
| Conflict of interest | Ministry of Health/health agency may commission a study to evaluate its own actions | Research versus marketing | Public health agency evaluating its own interventions | |
| Autonomy | Units of study | Communities, institutions, Individuals | Individuals | Communities, institutions, individuals |
| Consent | Group permission, gatekeeper | Individuals | Waived (provision of information), permission, gatekeeper | |
| Community engagement | Necessary to engage with and inform participants | Often not necessary, subjects informed during individual consent process | Generally necessary to engage with and inform communities | |
| Opt-out possibilities | Sometimes not possible to opt out without imposing large burden | Integral to informed consent process | May not be possible to opt out without imposing large burden | |
| Gatekeepers | Appropriate choice of person/institution | Often not required/relevant | If required, appropriate choice of representative | |
| Non-maleficence | Risks/harm | May not be the same recipient as beneficiary | Usually risk taken by beneficiary (phase III, IV clinical trials) | Risks may apply to individuals while benefits may accrue to communities |
| Broader risks may not be obvious upfront | ||||
| How to balance benefits gained by one group and risks taken by another? | May infringe on individual autonomy for common good | |||
| Long term risks may not be initially apparent/recognised | ||||
| Minimal risk definition | Definition of ‘minimal risk’ | Risk to the individual participant should be acceptable relative to potential benefit | Definition of 'minimal risk' | |
| Stigmatisation | Of groups selected for study | Less risk because of individual consent | Of communities receiving an intervention | |
| Institutional reputational risks, may be difficult to 'blind' data | ||||
| Beneficence | Benefits | Benefits may be gained by groups not directly targeted by study | Usually gained by individual who takes the risk | Usually common good, extend to broader local population |
| How to balance benefits gained by one group and risks taken by another? | Balance cost-effectiveness versus priority of need | |||
| Minimal benefit | Study should only be undertaken if reasonable expectation of meaningful outcomes | Clinical equipoise should guard against 'useless' study | Study should only be undertaken if reasonable expectation of meaningful outcomes | |
| Justice | Inclusion in study | Representation of vulnerable groups | Eligibility and exclusion criteria clear | Entire community |
| Fair subject selection | Vulnerable groups | |||
| Equity | Concern not to aggravate inequalities or even work towards more equitable care | Usually 'inequity' accepted to some degree for randomisation or inclusion/exclusion criteria | Justice and fairness are key | |
| Community/stakeholder engagement | Frequently required, may depend on nature of intervention to be tested | Often not necessary, subjects informed during individual consent process | Frequently required, may depend on nature of intervention to be tested | |
| Standard of care | Relevant especially for control arm | Often clear | Relevant especially if control group | |
| Equipoise | May be procedural or contextual equipoise, usually not clinical | Clinical equipoise required | May be contextual and clinical | |
| Dissemination of findings | To policy makers to impact policy, other researchers, decision makers, communities who participated | Obligation to report both positive and negative results of clinical trials, at the very least in a publicly available clinical trials registry. Outcome of all clinical research to be reported back to research participants where relevant | To public health policy makers to impact policy, other researchers, community, health workers |
Concepts developed from references.6 14–21 27–29
Current challenges in research ethics committees review of health policy and systems research
| Challenge | Relevant considerations | Examples |
| What to review |
Is the study research or not? Does the study require full review, expedited review, waiver of review? ‘Piggy-backing’ problem: as a project evolves an unanticipated research component may develop requiring further/additional review | Debate exists whether quality improvement or monitoring and evaluation exercises are indeed research. |
| Research components |
What is the intervention and why (ie, prioritisation)? Define who/what subject of research is (ie, justice, equity considerations) What level of consent is required/feasible? What methods are used? Are they appropriate for research question? Does the study increase risk/burden/compromise interests in any way that would not have occurred if learning activity were not present? Identify possible consequences or problems? Who assumes ancillary care responsibilities? Have all stakeholders been meaningfully engaged in planning phase? | In an intervention providing taxi vouchers to pregnant women as incentives to increase institutional deliveries, performance at local clinics will be monitored to determine impact of voucher intervention on outcomes. |
| Potential conflict of interest |
Role of those commissioning or funding the research? | The state may commission a study to evaluate its own interventions/programmes |
| How to deal with individual risk/autonomy |
Balance risk and benefits for individuals versus community or health system Is ‘minimal benefit’ a form of potential harm (ie, is the study worth doing?) ‘Reputational risk’ to researchers, states, stakeholders The risks of health policy and systems research are experienced at different levels; therefore, more comprehensive global risk assessment must be required. Redefine concept of an ‘adverse event’ outside of clinical research, as the perspective is far broader in health policy and systems research | In health policy and systems research, those exposed to the risks of an intervention may be different from those who benefit from the intervention. For example, an intervention testing a vaccine to prevent transmission of malaria from an infected individual to others would expose the vaccinated individual to the risk of vaccination but only protect other individuals from malaria. |
| Use of incentives |
Unclear if incentives are moral in any form in a poor country (size and nature of incentive) If questionable sustainability of incentives for the long term, they may not be ethical to study | Incentives used in studies conducted in communities/regions where poverty is high may induce participation that would otherwise have been against the will of a participant for example, payment for blood sampling. |
| Justice |
Ethical value of repeating an intervention known to be valid elsewhere (clinical versus contextual equipoise) Is randomisation justified? What is an acceptable standard of care for control groups? Research may be a tool to introduce an intervention into a country but this may exacerbate regional inequalities at least initially | A stepped-wedge trial evaluating delivery of a new vaccine, known to be highly effective in prevention of diarrhoeal illness, in a community with historical reluctance to vaccination may be justifiable to evaluate acceptability of the vaccine in the community, but given the known effectiveness of the vaccine, leaving ‘control’ communities unvaccinated especially in the early stages of the study could be interpreted as permitting harm. |
| Legal concerns |
Implementation of interventions outside the law may be tolerated (eg, testing an unapproved medication or task shifting), but where does the accountability lie for adverse events? | Study of the effectiveness of using community health workers to diagnose and empirically treat pneumonia in young children in rural areas goes beyond the usual scope of practice of the community health workers. If a child is misdiagnosed or incorrectly treated by a community health worker, where does the responsibility lie? |
| Post-study |
Must there be assurance of sustainability post-study? Does the study enhance local infrastructure/research capacity? | The use of incentives to induce changes in health behaviour may not be sustainable long term. |
| Role of research ethics committee |
Distinguish ethical risks inherent to the public health practice being studied versus those intrinsic to the research study itself What is the research ethics committee's role (if any) in ensuring appropriate post-study activities? | Randomisation to intervention versus control itself may constitute a risk if an intervention is known to be effective |
| Strategies to improve quality of ethical review |
Research ethics committees must be familiar enough with specific relevance of ethical issues to health policy and systems research to reduce variability across sites Research ethics committees should include representatives of variety of stakeholder groups to enhance appropriateness of the review process and anticipation of challenges Research ethics committees must be independent bodies and not tools of external stakeholders. Engagement between research ethics committees and researchers and establishment of a guidance tool with ethical practice expectations to reduce perceived ‘rubber stamping’ role of research ethics committees | Research committees reviewing the same health policy and systems research protocol at various sites may issue different reports which may cause important delays in study initiation and create difficulties for researchers conducting studies in multiple sites. |
Key features to be considered in development of a guidance tool/ethical framework for health policy and systems research
| Feature | Comments |
| What is health policy and systems research? |
Definitions outlined by Alliance for Health Policy and Systems Research Range of study methods and types with examples Develop a matrix with links to database of cases as examples Health policy and systems research does not always involve an intervention, may be policy analysis, strategy study |
| Identify key areas of difference between health policy and systems research and clinical research |
Scoping review findings Existing documents outlining methods/codes of conduct Ottawa Statement Secretary's Advisory Committee on Human Research Protections WHO guidelines on patient safety research |
| Identify target audience for document |
Research ethics committee members Researchers Public health practitioners Non-governmental organisations Policy makers Research funders Healthcare workers |
| Goal of document |
Structured tool highlighting ethical domains where consideration and elaboration are required as a guide design and conduct of health policy and systems research and ethical review of health policy and systems research Living document, with integration of ongoing feedback and evaluation of the review process by the research ethics committee and researchers |
| Does ethics review always need to be done? |
Does health policy and systems research increase risk/burden/compromise interests in way that would not have occurred if learning activity were not present? If yes, review likely required. How to enhance review? Identify ethical issues that need additional attention Avoid additional burden for the research ethics committee (emphasise that health policy and systems research review is not an additional review, it is a different approach to the review) |
| Identify study participants at multiple levels |
Individual: for example, definition of a participant in Ottawa statement
Communities Districts Institutions Policies |
| Emphasis on respect for researchers and their perspective |
Ensure good understanding of researcher's purpose/meaning Importance of written communication between researcher and the research ethics committee |
| Highlight challenges particular to ethical review of health policy and systems research |
Responsiveness to local needs Blurring boundary between research and clinical practice Balance need for ethical guidance versus need for more/better empirical evidence to understand issues/challenges and improve health system functioning Question of equipoise should be clearly answered, how a given health policy and systems research project achieves equipoise Distinguish between ethics review, scientific review and funding review Evolving research field Units of analysis Autonomy and risk/benefit of research in groups, imbalance between risk and benefit accrued by different groups/individuals Ancillary care responsibilities What are the ethical duties of all stakeholders? Who owns responsibility for study and outcomes? What is the appropriate response after a project is complete? When other forms of oversight might be needed, even if activities are not research? |